0000950170-24-030311.txt : 20240312 0000950170-24-030311.hdr.sgml : 20240312 20240312200443 ACCESSION NUMBER: 0000950170-24-030311 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240309 FILED AS OF DATE: 20240312 DATE AS OF CHANGE: 20240312 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Machatha Stephen CENTRAL INDEX KEY: 0001836354 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36332 FILM NUMBER: 24744161 MAIL ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aldeyra Therapeutics, Inc. CENTRAL INDEX KEY: 0001341235 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-761-4904 MAIL ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: Aldexa Therapeutics, Inc. DATE OF NAME CHANGE: 20130102 FORMER COMPANY: FORMER CONFORMED NAME: Neuron Systems Inc DATE OF NAME CHANGE: 20051012 4 1 ownership.xml 4 X0508 4 2024-03-09 0001341235 Aldeyra Therapeutics, Inc. ALDX 0001836354 Machatha Stephen C/O ALDEYRA THERAPEUTICS, INC. 131 HARTWELL AVENUE LEXINGTON MA 02421 false true false false Chief Development Officer false Common Stock 2024-03-11 4 S false 18231 3.4064 D 255032 D Common Stock 2024-03-12 4 S false 11537 3.164 D 243495 D Common Stock 211 I See footnote Stock Option (right to buy) 3.62 2024-03-09 4 A false 405450 0.00 A 2034-03-08 Common Stock 405450 405450 D These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the settlement of certain time-based restricted stock unit awards. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.27 to $3.58. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. These shares of common stock were sold by the Reporting Person for tax withholding and tax planning purposes in connection with the settlement of certain time-based restricted stock unit awards. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.11 to $3.31. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. These shares are held directly by the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership over these shares for purposes of Section 16 or for any other purposes. The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2024. /s/ Stephen Machatha 2024-03-12